Don't misuse patents to curb market entry of biosimilars

06/14/2013 | RxObserver blog

Patents help protect the significant investments tied to the development of new drugs and should never be abused to prevent the market entry of legitimate competitors, Edward C. Lawrence writes. Efforts to impede the pathway to biosimilar approval are a brake on innovation and will hurt consumers, Lawrence writes.

View Full Article in:

RxObserver blog

Published in Brief: